Understanding how LDOC1 affects tumor growth in high-risk ependymoma in children
Epigenetic regulation of LDOC1 drives tumor biology in high risk ependymoma
This study is looking at how a gene called LDOC1 affects the growth of a tough brain tumor called high-risk ependymoma, which mostly affects kids, to find new ways to treat it better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10866345 on NIH RePORTER |
What this research studies
This research investigates the role of a gene called LDOC1 in the development of high-risk ependymoma, a type of brain tumor that primarily affects children. The study aims to understand how the silencing of LDOC1 contributes to tumor growth and relapse, particularly in a common subtype known as posterior fossa Group A. Researchers will use advanced techniques like single-cell RNA sequencing to explore the mechanisms behind LDOC1's influence on tumor biology and its interaction with signaling pathways. By examining these factors, the research seeks to identify potential new therapeutic targets for treating this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with high-risk ependymoma, particularly those with the posterior fossa Group A subtype.
Not a fit: Patients with other types of brain tumors or those who do not have ependymoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective treatments for children with high-risk ependymoma, potentially improving survival rates.
How similar studies have performed: While research on ependymoma is ongoing, this specific approach focusing on LDOC1 and its epigenetic regulation is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Foreman, Nicholas K — University of Colorado Denver
- Study coordinator: Foreman, Nicholas K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.